Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2024-04-18 DOI:10.1080/09546634.2024.2340107

Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, Stephan Jeff Rustenbach, Ulrich Mrowietz, Matthias Augustin

引用次数: 0

Abstract

Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although bro...

查看原文本刊更多论文

布达鲁单抗的实际疗效和药物存活率：德国银屑病登记 PsoBest 的结果

Brodalumab是一种靶向白细胞介素-17受体A（IL-17RA）的人类单克隆抗体，已在美国和欧盟获批用于治疗成人中重度斑块状银屑病。虽然布罗...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.